In Vitro and In Vivo Synergetic Radiotherapy with Gold Nanoparticles and Docetaxel for Pancreatic Cancer

Abdulaziz Alhussan,Nolan Jackson,Norman Chow,Ermias Gete,Nicole Wretham,Nancy Dos Santos,Wayne Beckham,Cheryl Duzenli,Devika B. Chithrani

DOI: https://doi.org/10.3390/pharmaceutics16060713

IF: 6.525

2024-05-27

Pharmaceutics

Abstract:This research underscores the potential of combining nanotechnology with conventional therapies in cancer treatment, particularly for challenging cases like pancreatic cancer. We aimed to enhance pancreatic cancer treatment by investigating the synergistic effects of gold nanoparticles (GNPs) and docetaxel (DTX) as potential radiosensitizers in radiotherapy (RT) both in vitro and in vivo, utilizing a MIA PaCa-2 monoculture spheroid model and NRG mice subcutaneously implanted with MIA PaCa-2 cells, respectively. Spheroids were treated with GNPs (7.5 μg/mL), DTX (100 nM), and 2 Gy of RT using a 6 MV linear accelerator. In parallel, mice received treatments of GNPs (2 mg/kg), DTX (6 mg/kg), and 5 Gy of RT (6 MV linear accelerator). In vitro results showed that though RT and DTX reduced spheroid size and increased DNA DSBs, the triple combination of DTX/RT/GNPs led to a significant 48% (p = 0.05) decrease in spheroid size and a 45% (p = 0.05) increase in DNA DSBs. In vivo results showed a 20% (p = 0.05) reduction in tumor growth 20 days post-treatment with (GNPs/RT/DTX) and an increase in mice median survival. The triple combination exhibited a synergistic effect, enhancing anticancer efficacy beyond individual treatments, and thus could be employed to improve radiotherapy and potentially reduce adverse effects.

pharmacology & pharmacy

What problem does this paper attempt to address?

This paper aims to address the challenges in the treatment of pancreatic cancer, especially by combining nanotechnology with traditional therapies to improve the treatment efficacy. Specifically, the objective of the study is to enhance the treatment effect on pancreatic cancer by exploring the synergistic effect of gold nanoparticles (GNPs) and docetaxel (DTX) as potential radiosensitizers in radiotherapy (RT). In vitro, the MIA PaCa - 2 single - cell spheroid model was used, and in vivo, the NRG mouse model with subcutaneous implantation of MIA PaCa - 2 cells was used. Through these models, the researchers evaluated the synergistic effect of the combined use of GNPs, DTX and RT, aiming to optimize the treatment effect while reducing the adverse effects on healthy tissues.

The main problem of the study lies in how to use nanotechnology to improve the treatment effect of pancreatic cancer, especially by adding gold nanoparticles and docetaxel to the existing chemotherapy and radiotherapy regimens, in order to achieve better tumor control effects and possibly reduce the current radiotherapy and chemotherapy doses, thereby protecting normal tissues from the risk of over - exposure.